多发性骨髓瘤的CAR-T治疗研究进展  

Research Development of CAR-T Cell Therapies for Multiple Myeloma

作　　者：贾庆华 马俊 张富婷 牛廷献 JIA Qinghua;MA Jun;ZHANG Futing;NIU Tingxian(Department of Clinical Laboratory,Key Laboratory of Stem Cells and Gene Drug of Gansu Province,The 940th Hospital of Joint Logistics Support Force of Chinese People′s Liberation Army,Lanzhou 730050,China;Laboratory of Preclinical Medicine,Key Laboratory of Stem Cells and Gene Drug of Gansu Province,The 940th Hospital of Joint Logistics Support Force of Chinese People′s Liberation Army,Lanzhou 730050,China)

机构地区：[1]联勤保障部队第九四〇医院检验科,兰州730050 [2]联勤保障部队第九四〇医院基础医学实验室甘肃省干细胞与基因药物重点实验室,兰州730050

出　　处：《医学综述》2022年第6期1108-1114,共7页Medical Recapitulate

基　　金：甘肃省自然科学基金(18JR3RA407)。

摘　　要：多发性骨髓瘤(MM)是一种几乎无法治愈的浆细胞恶性肿瘤。嵌合抗原受体(CAR)是结合抗原识别域和T细胞信号域的融合蛋白,通过基因工程表达CAR的T细胞(即CAR-T)可以特异性地识别和结合肿瘤细胞抗原,激活的T细胞会杀死肿瘤细胞。CAR-T免疫治疗为MM的治疗提供了新思路。目前MM的治疗靶点包括B细胞成熟抗原、CD19、CD38、CD138、免疫球蛋白κ轻链、信号淋巴细胞激活分子家族成员F7等。CAR-T治疗也面临缺乏有效性、肿瘤外毒性、靶抗原丢失、干扰可溶性蛋白等问题,影响CAR-T治疗MM的效果。今后研究的重点将集中在联合策略、双特异性和多特异性CAR-T疗法以及个体化治疗方案的制订,以提高MM患者治疗的安全性、有效性。Multiple myeloma(MM)is an almost incurable malignancy of plasma cells.Chimeric antigen receptor(CAR)are fusion proteins incorporating antigen-recognition domains and T-cell signaling domains.T-cells genetically engineered to express CAR can specifically recognize and combine antigens of tumor.The activated T cells can kill the tumor cells.CAR-T cell therapy offers a new way for the treatment of MM.Current therapeutic targets of MM include B-cell maturation antigen,CD19,CD38,D138,immunoglobulinκlight chain,signal lymphocyte activating molecule family member F7,etc.However,several potential limitations such as lack of effectiveness,off-tumor toxicities,and antigen loss or interference with soluble proteins could hamper the efficacy of CAR-T in the treatment of MM.In future,the research will focus on the combination strategies,bispecificity and multi-specificity of CAR-T cell therapy,and developing individualized treatment regimens,in order to improve the safety and efficacy of the treatment of MM patients.

关 键 词：多发性骨髓瘤 嵌合抗原受体T细胞 细胞免疫治疗 肿瘤相关靶抗原 

分 类 号：R392.11[医药卫生—免疫学]